JZL184

JZL184 is a selective inhibitor of monoacylglycerol lipase (MAGL). MAGL is an enzyme primarily responsible for the hydrolysis of the endocannabinoid 2-arachidonoylglycerol (2-AG). By inhibiting MAGL, JZL184 increases the levels of 2-AG in the brain. 2-AG is a key signaling molecule in the endocannabinoid system, which plays a role in various physiological processes including pain perception, appetite, mood, and memory.

Researchers utilize JZL184 as a pharmacological tool to investigate the functions of the endocannabinoid system. Its selectivity for MAGL makes it valuable for studying the specific contribution of 2-AG hydrolysis to different biological pathways. Studies involving JZL184 have explored its potential therapeutic applications, particularly in areas such as pain management, neuroprotection, and the treatment of anxiety and depression. However, it is important to note that JZL184 is a research chemical and is not approved for human use. Its development and clinical application are still in early stages of research.